case_images: PMC11331146_01
case_images: Hematoxylin-eosin (HE) staining and immunohistochemistry (IHC) of CT-guided biopsy of the left iliac mass. (A) HE staining showed poorly differentiated osteosarcoma (x200); (B) IHC examination revealed the left iliac mass was positive for PD-L1 (x200).
case_images: OTT-17-661-g0001.jpg
case_images: PMC11331146_01_OTT-17-661-g0001.jpg
case_images: f0001
case_images: CT-guided biopsy was performed against the left-iliac mass and the histologic examination showed poorly differentiated osteosarcoma (Figure 1A) and immunohistochemical stains suggested positivity for PD-L1 expression (TPS >= 95%) (Figure 1B).
case_images: Computerized tomography (CT) was performed before and after sintilimab plus anlotinib therapy. (A-D) CT scan of the mass in the right lung, the mediastinal lymph nodes, the mass in the right pubic and the mass in the subcutaneously left iliac region before the treatment, respectively (arrow); (E-H) CT scan of the mass in the right lung, the mediastinal lymph nodes, the mass in the right pubic and the mass in the subcutaneously left iliac region after 2 cycles of sintilimab plus anlotinib therapy, respectively (arrow); (I-L) CT scan of the mass in the right lung, the mediastinal lymph nodes, the mass in the right pubic and the mass in the subcutaneously left iliac region after 12 cycles of sintilimab plus anlotinib therapy, respectively (arrow).
case_images: OTT-17-661-g0002.jpg
case_images: PMC11331146_01_OTT-17-661-g0002.jpg
case_images: f0002
case_images: On January 5, 2020, after 2 cycles of this regimen, a stable disease (SD) with 20% shrinkage of volume was observed (Figure 2A-H). Twelve cycles of treatment later, a CT scan showed partial response (PR) of the mass, especially in the lung, mediastinal lymph nodes, right pubic and subcutaneously left iliac region (Figure 2I-L).